Interferons and systemic sclerosis: Correlation between interferon gamma and interferon-lambda 1 (IL-29)

Autoimmunity

Volumn 48, Issue 7, 2015, Pages 429-433

  Dantas, Andréa Tavares ^a   Gonçalves, Sayonara Maria Calado ^a   Pereira, Michelly Cristiny ^a   De Almeida, Anderson Rodrigues ^a   Marques, Cláudia Diniz Lopes ^a   De Melo Rego, Moacyr Jesus Barreto ^a   Da Rocha Pitta, Ivan ^a   Duarte, Angela Luzia Branco Pinto ^a   Da Rocha Pitta, Maira Galdino ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cytokine; interferon gamma; interferon lambda1; interleukin 29; scleroderma

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 29; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE; MYOSITIS; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKELETAL MUSCLE;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; SCLERODERMA, SYSTEMIC;

EID: 84946573058     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2015.1054028     Document Type: Article

References (32)

1. Baraut, J., L. Michel, F. Verrecchia, and D. Farge. 2010. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun. Rev. 10: 65-73.
2. O'Reilly, S., T. Hügle, and J. M. van Laar. 2012. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 51: 1540-1549.
3. Chizzolini, C., N. C. Brembilla, E. Montanari, and M. E. Truchetet. 2011. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun. Rev. 10: 276-281.
4. Needleman, B. W., F. M. Wigley, and R. W. Stair. 1992. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum. 35: 67-72.
5. Hasegawa, M., M. Fujimoto, K. Kikuchi, and K. Takehara. 1997. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J. Rheumatol. 24: 328-332.
6. Matsushita, T., M. Hasegawa, Y. Hamaguchi, et al. 2006. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J. Rheumatol. 33: 275-284.
7. Postlethwaite, A. E., M. A. Holness, H. Katai, and R. Raghow. 1992. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 90: 1479-1485.
8. Oriente, A., N. S. Fedarko, S. E. Pacocha, et al. 2000. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J. Pharmacol. Exp. Ther. 292: 988-994.
9. Commins, S., J. W. Steinke, and L. Borish. 2008. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J. Allergy Clin. Immunol. 121: 1108-1111.
10. Gallagher, G., N. J. Megjugorac, R. Y. Yu, et al. 2010. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J. Interferon Cytokine Res. 30: 603-615.
11. Wu, Q., Q. Yang, H. Sun, et al. 2013. Serum IFN-lambda1 is abnormally elevated in rheumatoid arthritis patients. Autoimmunity. 46: 40-43.
12. Li, M., X. Liu, Y. Zhou, and S. B. Su. 2009. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 86: 23-32.
13. Jordan, W. J., J. Eskdale, S. Srinivas, et al. 2007. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 8: 254-261.
14. Srinivas, S., J. Dai, J. Eskdale, et al. 2008. Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology. 125: 492-502.
15. Wu, Q., Q. Yang, E. Lourenco, et al. 2011. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res. Ther. 13: R88.
16. Masi, A. T., G. P. Rodnan, T. A. Medsger, et al. 1980. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 23: 581-590.
17. LeRoy, E. C., and T. A. Medsger. 2001. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28: 1573-1576.
18. Clements, P., P. Lachenbruch, J. Siebold, et al. 1995. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J. Rheumatol. 22: 1281-1285.
19. Zahn, S., C. Rehkamper, B. M. Kummerer, et al. 2011. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J. Invest. Dermatol. 131: 133-140.
20. Wang, F., L. Xu, X. Feng, et al. 2012. Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis. Arthritis Res. Ther. 14: R228.
21. McGaha, T. L., and C. A. Bona. 2002. Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun. Rev. 1: 174-181.
22. Gourh, P., F. C. Arnett, S. Assassi, et al. 2009. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res. Ther. 11: R147.
23. Scala, E., S. Pallotta, A. Frezzolini, et al. 2004. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin. Exp. Immunol. 138: 540-546.
24. Radstake, T. R., L. van Bon, J. Broen, et al. 2009. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 4: e5903.
25. Randone, S. B., S. Guiducci, and M. M. Cerinic. 2008. Musculoskeletal involvement in systemic sclerosis. Best Pract. Res. Clin. Rheumatol. 22: 339-350.
26. Kalovidouris, A. E., and Z. Plotkin. 1995. Synergistic cytotoxic effect of interferon-gamma and tumor necrosis factor-alpha on cultured human muscle cells. J. Rheumatol. 22: 1698-1703.
27. Kalovidouris, A. E., C. A. Horn, and Z. Plotkin. 1994. The role of cytokines in polymyositis. III. Recombinant human interferongamma enhances T cell adhesion to cultured human muscle cells. Arthritis Rheum. 37: 907-914.
28. Kalovidouris, A. E., Z. Plotkin, and D. Graesser. 1993. Interferongamma inhibits proliferation, differentiation, and creatine kinase activity of cultured human muscle cells II. A possible role in myositis. J. Rheumatol. 20: 1718-1723.
29. Preusse, C., H. H. Goebel, J. Held, et al. 2012. Immunemediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am. J. Pathol. 181: 2161-2171.
30. Dai, J., N. J. Megjugorac, G. E. Gallagher, et al. 2009. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood. 113: 5829-5838.
31. Jordan, W. J., J. Eskdale, M. Boniotto, et al. 2007. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 8: 13-20.
32. Xu, L., X. Feng, W. Tan, et al. 2013. IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients. Arthritis. Res. Ther. 15: R170.